Brief: Royalty Pharma And Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement For Niktimvo
04/11/2024 21:19
Nov 4 (Reuters) - Royalty Pharma PLC RPRX.O :
* ROYALTY PHARMA AND SYNDAX PHARMACEUTICALS ENTER INTO $350
MILLION ROYALTY FUNDING AGREEMENT FOR NIKTIMVO
Source text: ID:nGNX9Xtw2b
Further company coverage: RPRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)